Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| University Clinic of In… | Healthcare Services | 50.0% | 97th pct | 268 |
| In Vitro Laipi | Healthcare Services | 22.1% | 80th pct | 268 |
| Davit Abuladzis Kartul-… | Healthcare Services | 15.9% | 68th pct | 268 |
| Pirveli Sameditsino Kli… | Healthcare Services | 10.0% | 51st pct | 268 |
| Davit Tatishvilis Janmr… | Healthcare Services | 7.6% | 44th pct | 268 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
| Ratio — FY 2024 | In Vitro Laipi | University Clinic of In… | Davit Tatishvilis Janmr… | Pirveli Sameditsino Kli… | Davit Abuladzis Kartul-… |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 29.9% | 86.3% | 28.5% | 92.8% | 95.0% |
| EBITDA Margin | 22.1% | 50.0% | 7.6% | 10.0% | 15.9% |
| EBITDAR | 1,763 | 2,832 | 769 | 1,370 | 838 |
| EBITDAR Margin | 27.3% | 50.0% | 14.7% | 28.8% | 18.7% |
| EBIT Margin | 19.7% | 18.3% | -0.1% | 1.2% | 14.0% |
| Net Profit Margin | 20.3% | 18.4% | -2.9% | -9.4% | 12.3% |
| Operating Expense % of Sales | 7.9% | 47.9% | 20.8% | 82.8% | 79.1% |
| Returns | |||||
| Return on Assets (ROA) | 32.5% | 4.8% | -11.9% | -12.3% | 65.9% |
| Return on Equity (ROE) | 34.7% | 7.0% | N/A | N/A | 76.1% |
| ROIC [EBIT / Invested Capital] | 87.0% | ||||
| 4.9% |
| -0.9% |
| 2.0% |
| 105.8% |
| Leverage & debt balances | |||||
| Debt-to-Assets | 0.0% | 29.4% | 142.9% | 121.2% | 0.0% |
| Debt-to-Equity | 0.00x | 0.43x | -1.62x | -2.92x | 0.00x |
| Debt-to-EBITDA | 0.00x | 2.27x | 4.50x | 9.25x | 0.00x |
| Equity-to-Assets | 93.5% | 68.7% | -88.2% | -41.4% | 86.6% |
| Net Debt | -2,325 | 6,240 | 1,790 | 4,374 | -133 |
| Cash & Equivalents | 2,325 | 196 | 8 | 11 | 133 |
| Total Debt | N/A | 6,436 | 1,798 | 4,384 | N/A |
| Liquidity & working capital | |||||
| Current Ratio | 1.18x | 2.42x | 0.19x | 0.03x | 3.78x |
| Quick Ratio | 1.18x | 2.35x | 0.19x | 0.03x | 3.78x |
| Cash Ratio | 0.88x | 0.10x | 0.00x | 0.00x | 1.18x |
| Total Current Assets | 3,090 | 4,887 | 440 | 142 | 426 |
| Total Current Liabilities | 2,629 | 2,016 | 2,307 | 5,057 | 113 |
| Inventory | N/A | 157 | N/A | N/A | N/A |
| Trade Receivables | 185 | 1,735 | 397 | 1,103 | 172 |
| Trade Payables | 238 | 367 | 319 | 400 | 48 |
| Net Working Capital | 460 | 2,871 | -1,867 | -4,915 | 313 |
| Net Working Capital % of Revenue | 7.1% | 50.6% | -35.7% | -103.2% | 7.0% |
| Trade Working Capital | -54 | 1,524 | 79 | 704 | 124 |
| Trade Working Capital % of Revenue | -0.8% | 26.9% | 1.5% | 14.8% | 2.8% |
| Change in Trade Working Capital | N/A | N/A | N/A | N/A | N/A |
| Turnover & efficiency | |||||
| Inventory Turnover | N/A | 4.96x | N/A | N/A | N/A |
| Days Inventory Outstanding (DIO) | N/A | 73.6 | N/A | N/A | N/A |
| Receivables Turnover | 35.03x | 3.27x | 13.17x | 4.32x | 26.00x |
| Days Sales Outstanding (DSO) | 10.4 | 111.7 | 27.7 | 84.6 | 14.0 |
| Payables Turnover | 19.02x | 2.12x | 11.76x | 0.86x | 4.68x |
| Days Payable Outstanding (DPO) | 19.2 | 172.4 | 31.0 | 424.5 | 77.9 |
| Cash Conversion Cycle | -8.8 days | 13.0 days | -3.3 days | -339.9 days | -63.9 days |
| Asset Turnover | 1.60x | 0.26x | 4.16x | 1.32x | 5.33x |
| Cash flow & dividends | |||||
| Operating Cash Flow | N/A | 2,249 | 6 | 5,190 | N/A |
| Free Cash Flow (OCF − Capex proxy) | N/A | 1,845 | 6 | 5,190 | N/A |
| Cash Conversion (OCF / EBITDA) | N/A | 79.4% | 1.5% | 1095.4% | N/A |
| Dividends Declared | N/A | 0 | N/A | N/A | N/A |
| Dividend Payout Ratio | N/A | 0.0% | N/A | N/A | N/A |